Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITAF: TAF vs TDF in Chronic Hepatitis B
NCT03356834Phase 4Completed
- Sponsor
- Humanity & Health Research Centre
- Start
- Dec 2017
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Humanity & Health Research Centre. Primary endpoint: Antiviral response of TAF at 60 months. Started Dec 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03356834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356834.